Oxidative metabolism and urotensin-II levels among bipolar disorder patientsin a manic episode

According to the previous studies, it has been noted many times that oxidative balance is disrupted in bipolar disorder. However, we did not found any research investigating the relationship between Urotensin-II (U-II) levels and oxidative metabolism among bipolar disorder patients in the literature. In this study, we aimed to investigate the relationship between U-II levels and oxidative metabolism among bipolar disorder patients in the manic episode.Forty-two patients diagnosed as bipolar disorder manic episode according to DSM-5 and 55 healthy controls enrolled in the study. Serum total antioxidant status (TAS), total oxidant status (TOS), nitric oxide (NO), U-II and oxidative stress index (OSI) measurements were done in the biochemistry laboratory of Gaziantep University. When TAS, TOS, OSI, NO, and U-II levels were compared between bipolar disorder manic episode patients and control group; TAS, TOS, OSI, NO and U-II levels were significantly higher in the patient group than the control group (p=0.003, p=0.001, p=0.001, p=0.001 and p=0.009 respectively). According to the correlation analysis, U-II levels were found to have a weak linear correlation in the positive direction with TOS and OSI (r=0.326, p=0.035 for TOS; and r=0.369, p=0.016 for OSI). In the earlier studies, data have been obtained about the effects of U-II on behavior, sleep, inflammatory system and oxidative metabolism and relevant hypotheses have been established. In the light of these studies in the literature, our study proposes that increased U-II levels could be a factor affecting the elevated oxidative stress and inflammation in patients with bipolar disorder manic episode. Our study is the first one to examine relationship between U-II levels and oxidative parameters in manic episode of bipolar disorder; therefore, it may significantly contribute to the literature.

PDF

___

1. Akkaya C, Deniz G, CAngür S, et al. The relationship between the duration of drug use and the bipolar disorder patients’ sociodemographic and clinical characteristics. Turk Psikiyatri Derg. 2014;25:94-105.

2. Andreazza AC, Cassini C, Rosa AR, et al. Serum S100B and antioxidant enzymes in bipolar patients. J Psychiatr Res. 2007;41:523-9.

3. Steckert AV, Valvassori SS, Moretti M, et al. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res. 2010;35:1295-301.

4. Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008;107:89-94.

5. Savas HA, Gergerlioglu HS, Armutcu F, et al. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry. 2006;7:51-5.

6. Erdem M, Akarsu S, Pan E, et al. Bipolar disorder and oxidative stress. Psychiatr Behavioral Sci. 2014;4:70-9.

7. Onan D, Hannan RD, Thomas WG. Urotensin II: The old kid in town. Trends Endocrinol. Metab. 2004;15:175-82.

8. Hunt BD, Leong LN, Lambert DG. A rat brain atlas of urotensin-II receptor expression and a review of central urotensin-II effects. Naunyn-Schmied Arch Pharmacol. 2010;382:1–31.

9. Bulbul F, Alpak G, Unal A, et al. New molecule in the etiology of schizophrenia: Urotensin II. Psychiatr Clin Neurosci. 2014;68:133–6.

10. Gartlon J, Parker F, Harrison DC et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl). 2001;155:426–33.

11. Huitron-Resendiz S, Kristensen MP, Sanchez-Alavez M, et al. Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. J Neurosci. 2005;25:5465–74.

12. Osman Hasan Tahsin Kilic, Ihsan Aksoy, Gulcin Cinpolat Elboga, et al. Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients. Psychiatr Clin Psychopharmacol. 2019;29:151-7.

13. Oral E, Halici Z, Cinar I, et al. Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels. Clin Psychopharmacol Neurosci. 2019;17:211–21.

14. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clinical Biochemistry. 2004;37:112-9.

15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clinical biochemistry. 2005;38:1103-11.

16. Yumru M, Savas HA, Kalenderoglu A, et al. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1070-4.

17. Kuloglu M, Ustundag B, Atmaca M, et al. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002;20:171-5.

18. Wang J-F, Shao L, Sun X, et al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disorders. 2009;11:523–9.

19. Andreazza AC, Kauer-Sant’anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord. 2008;111:135-44.

20. Kunz M, Gama CS, Andreazza AC, et al. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008;32:1677-81.

21. Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34:263-71.

22. Ozcan ME, Gulec M, Ozerol E, et al. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004;19:89-95.

23. Gawryluk JW, Wang JF, Andreazza AC, et al. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacology. 2011;14:123–30.

24. Ranjekara PK, Hinge A, Hegde VM, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiat Res. 2003;121:109–22.

25. Saglam AD, Tiryaki A, Ozkorumak E, et al. Nitric Oxide and Asymmetrical Dimethylarginine Levels in Acute Mania. Klinik Psikofarmakoloji Bülteni. 2012;22:10-6.

26. Duygu K, Erol A. The Importance of Urotensin and Urotensin Receptors in Cardiovascular System. J Clin Analytical Med. 2014;1:1-7

27. d’Emmanuele di Villa Bianca R, Cirino G, et al. Urotensin II: A novel target in human corpus cavernosum. J. Sex. Med. 2010;7:1778–86.

28. Culha AF, Osman O, Dogangun Y, et al. Changes in regional cerebral blood flow demonstrated by Tc-HMPAO SPECT in euthymic bipolar patients. Eur Arch Psychiatry Clin Neurosci. 2008;258:144-51.

29. Agarwal N, Bellani M, Perlini C, et al. Increased fronto-temporal perfusion in bipolar disorder. J Affect Disord. 2008;110:106-14.

30. Kronfol Z, Remick DG. Cytokines and the Brain: Implications for clinical psychiatry. Am J Psychiatr. 2000;157:683-94.

31. Kim YK, Na KS, Shin KH, et al. Cytokine imbalance in the pathophysiology of major depressive disorder. Progress Neuropsycho pharmacology Biological Psychiatry 2007;30:1044-53.32.

32. Uyanik V. Bipolar I bozukluk tanılı hastaların tedavi öncesi ve sonrası sitokin düzeylerinin değerlendirlmesi. Uzmanlık tezi. Trakya Üniversitesi. 2010;11

33. Johns DG, Ao Z, Naselsky D, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:238–50.

34. Birker-Robaczewska M, Boukhadra C, Studer R, et al. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res. 2003;23:289–305.

35. Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004;176:117–23.

36. Hudson JI, Lipinski JF, Frankenburg FR, et al. Electroencephalographic sleep in mania. Arch Gen Psychiatry 1988;45:267-73.

37. Kupfer DJ, Wyatt RJ, Greenspan K, et al. Lithium carbonate and sleep in affective illness. Arch Gen Psychiatry 1970;23:35-40.

38. Huitron-Resendiz S, Kristensen MP, Sanchez-Alavez M, et al. Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. J Neurosci 2005;25:5465–74..